Diffuse Large B-Cell LymphomaNCT07862764
A Study to Assess Change in Disease State and Adverse Events in Korean Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Receiving Epcoritamab Injections
An observational study of Diffuse Large B-Cell Lymphoma, run by AbbVie.
Trial summary
Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) represents approximately 50% of all newly diagnosed patients with non-Hodgkin lymphoma. This study will assess adverse events and change in disease activity in adult Korean participants with DLBCL under routine clinical practice. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Diffuse Large B-Cell Lymphoma
- How many people
- 175 participants
- Where
- No sites listed yet
- Study dates
- 2 Oct 2026to Nov 2029
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Who may be able to join
- Participants who have agreed to receive epcoritamab treatment according to the latest approved local label or have already started epcoritamab treatment as per the approved label information at the time of the first administration of epcoritamab.
- Participants who voluntarily agree to participate in this study and sign informed consent.
Who cannot join
- Contraindication to epcoritamab as listed on the latest approved local label.
- Currently participating in another clinical research except observational study.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Post Marketing Safety Study to Evaluate the Safety and Effectiveness of Epcoritamab in Korean Adult Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)
Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) represents approximately 50% of all newly diagnosed patients with non-Hodgkin lymphoma. This study will assess adverse events and change in disease activity in adult Korean participants with DLBCL under routine clinical practice.
Epcoritamab is an approved drug for the treatment of DLBCL and FL. Approximately 175 adult participants who are prescribed epcoritamab by their doctors will be enrolled sites in Korea.
Read more
Participants will receive epcoritamab as prescribed by their physician. Participants will be followed for up to 24 weeks.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Read the detailed description
Prospective and retrospective study
- Conditions
- Diffuse Large B-Cell Lymphoma
- Keywords
- Diffuse Large B-Cell Lymphoma, Epcoritamab, Cancer
- Medical subject headings
- Lymphoma, Large B-Cell, Diffuse, Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Epcoritamab Participants | Participants treated with Epcoritamab in accordance with approved local label. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants with Adverse Event (AEs)
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An SAE is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above.
Measured: Up to Approximately 24 Weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Oct 2026
- Study start2 Oct 2026 (estimated)
- Primary completionNov 2029 (estimated)
- Study completionNov 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diffuse Large B-Cell LymphomaStudies of the same condition, open and under way.
- More trials run by AbbVieThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 175 participants (estimated)
Sponsor and investigators
- Lead sponsor
- AbbVie
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- ABBVIE INC., Study director, AbbVie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07862764
- Sponsor's protocol ID
- P24-482
- Status last verified
- Oct 2026
- First submitted
- 2 Oct 2026
- Last updated
- 7 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided